Tioma Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- August 16, 2016
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $86,000,000
Company Info
- Company Description
- Tioma Therapeutics has generated a portfolio of anti-CD47 antibodies that have the potential to surmount multiple checkpoints by which cancer evades the immune system. These antibodies are protected by a strong, multilayered intellectual property estate that includes composition-of-matter and uses of humanized anti-CD47 antibodies.
- Market
- Cancer Immunotherapy
- Location
- Brisbane, California, USA
- Coinvestors
- Novo Ventures, RiverVest Venture Partners, Roche Venture Fund, SR One